Weekly CAF chemotherapy for advanced breast cancer patients

Wei Shou Hwang, Chao A. Hsiung, Wann Sheng Ko, Chang Chung Wang, Jang Yang Chang, Gi Ming Lai, Ruey Kuen Hsieh, Chao Jung Tsao, Li Tzong Chen, Chi Kong Law, Ann Lii Cheng, Sheng F. Fan, Cheng Hwai Tzeng, Tzeon Jye Chiou, Jacqueline Whang-Peng

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalOncology (Switzerland)
Issue number4
Publication statusPublished - Jan 1 1997
Externally publishedYes


  • Advanced
  • Breast cancer
  • CAF
  • Phase II trial
  • Weekly

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Weekly CAF chemotherapy for advanced breast cancer patients'. Together they form a unique fingerprint.

Cite this